The current valuation score of Madrigal Pharmaceuticals Inc is 9.67, ranking 18 out of 384 in the Biotechnology & Medical Research industry. Its current P/E ratio is -36.17, which is -87.78% below the recent high of -4.42 and -29.07% above the recent low of -46.69.
P/E
Relevant data have not been disclosed by the company yet.
P/B
Relevant data have not been disclosed by the company yet.
P/S
Relevant data have not been disclosed by the company yet.
P/CF
Relevant data have not been disclosed by the company yet.